Our work with patients and caregivers is built on four commitments
Read more about our commitment to patients and caregivers here.
Patients and caregivers know better than anyone what it is like to live with a serious disease. We listen. And we learn from people’s experiences. We work together to create medicines that address the needs of people living with disease and achieve the results that matter to them.
The Novartis commitment to patients and caregivers
We recognize the importance of patients and caregivers understanding what they can expect from Novartis.
Disclosure of patient organization funding
Novartis annually discloses monetary and non-monetary support to patient organizations around the globe by June 30.
Our commitment – reporting 2025 progress
94%
early research programs
in general medicines were developed with patient perspective and insights before first-in-human trials (healthy volunteers).
7 194
new patients were reached through managed access programs
with 94% of requests approved for 37 compounds in 62 countries. MAPs provide access to locally unauthorized Novartis medicines.
81
clinical development projects
consulted people living with a disease on the design and/or conduct of clinical trials.
191
Clinical trials
with patient reported outcomes (PRO) were conducted in 81 countries.
402
Simplified summaries
from Phase I-IV clinical trials were sent to investigators to share with over 71 000 trial participants and posted on novartis.com/clinicaltrials.
30 m
Patients
reached through access approaches.
Clinical Trials
Managed access programs
Novartis managed access makes investigational or unapproved treatments available to eligible patients with serious or life-threatening diseases. Your physician may request access.
Diversity
Diversity in clinical trials helps us improve the quality of care for every patient, while also helping to address health inequities in society. We are working to improve both the diversity of patients enrolled in our clinical research and the investigators involved in our trials.
Collaborations with patient organizations
Listening to the CML patient community
Improving the patient experience and removing potential barriers to clinical trial participation
Patient organizations and Novartis
Working together with patient organizations and healthcare organizations helps us create better medicines. This collaboration is based on values of mutual respect, trust and transparency.
External funding
Novartis may provide funding to legitimate organizations to support its mission to discover new ways to improve and extend people's lives, advance scientific and medical knowledge, and supporting the communities where Novartis associates live and work.
Patient perspectives
Patients and caregivers know better than anyone what it is like to live with a serious disease. Visit our YouTube channel to watch our patient stories to learn more about insights from the patient community.
For questions about Novartis, medical inquiries about our products and/or information about services, we recommend you contact the Novartis office in your country. If you’re seeking a global list of products, visit our Global Product Portfolio.
*Based on 2025 data.